RenovoRx, Inc. (RNXT)
RNXTNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.24
+0.1677 (+15.66%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $56.94m
- P/E
- –
- EPS, last 4 quarters
- $-0.2800
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.7006 to $2.59
- Average volume
- 867.3k
- Previous close
- $1.07
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $7.13, +475.6% from here
Earnings
next estimate $-0.0500Next report
Dec 2025
0.0%
Mar 2026
0.0%
Jun 2026
+37.5%
Sep 2026
-40.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $266.0k | $238.0k | $563.0k | $909.0k |
| Gross profit | $213.0k | $210.0k | $479.0k | $766.0k |
| Operating income | -$3.20m | -$3.52m | -$3.47m | -$3.35m |
| Net income | -$2.91m | -$2.94m | -$3.52m | -$2.91m |
Last four quarters: revenue $1.98m, margin -621.7%, free cash flow –
News
8 latest- RenovoRx Q3 Earnings Call HighlightsMarketBeat · 4 days ago
- RenovoRx (RNXT) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue EstimatesZacks · 4 days ago
- RenovoRx Enrolls First Patient In UVM-Sponsored Pancreatic Cancer PRISM-TAMP Trial RTTNews · Oct 8, 2026
- 6 Biotech Stocks To Watch Ahead Of Key Catalysts: RenovoRx, Eupraxia, Connect Bio, Kardigan & More RTTNews · Sep 2, 2026
- Biotech Stocks At 52-Week Highs - RNXT +15%, EOLS, CRNX, APGE RTTNews · Sep 1, 2026
- Biotech Stocks At 52-Week Highs - RNXT +12%, BLSM, RVTY, ATRC, BFRI RTTNews · Aug 31, 2026
- Weekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal RTTNews · Aug 28, 2026
The company
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company commercializing RenovoCath, a novel, FDA-cleared device for local drug delivery designed to address significant unmet medical needs, with a focus on difficult-to-treat tumors. The Company is also evaluating intra-arterial gemcitabine (IAG) delivered via RenovoCath using RenovoRx's Trans-Arterial Micro-Perfusion (TAMP) platform as a novel drug-device product candidate for locally advanced pancreatic cancer.RenovoRx's patented TAMP platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, potentially improving safety, tolerance, and efficacy while minimizing the toxicities associated with systemic intravenous therapy. The Company's mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- renovorx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.